CD177 and neoplasm: It had a targeted effects on tumour cells and could combine specifically with a variety of cell surface receptors, such as cluster of differentiation 44 (CD44), receptor of HA-mediated motility(RHAMM), lymphatic vessel endothelial HA receptor-1 (LYVE-1) and cell surface HA receptor (HARE), which were overexpressed on the surface of tumour cells [9–11].